- Home
- SOAR vs EDSA Comparison
SOAR vs EDSA Comparison
Compare SOAR & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOAR | EDSA |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOAR | EDSA |
|---|---|---|
| Price | $1.28 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 250.8K | 29.0K |
| Earning Date | 11-13-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $1.55 |
| 52 Week High | $8.20 | $4.49 |
Technical Indicators
Market Signals| Indicator | SOAR | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 43.84 |
| Support Level | $1.18 | $1.67 |
| Resistance Level | $1.40 | $1.78 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 68.40 | 68.73 |
Price Performance
Historical ComparisonAbout SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.